Your session is about to expire
← Back to Search
Talquetamab + Daratumumab/Pomalidomide for Multiple Myeloma (MonumenTAL-3 Trial)
MonumenTAL-3 Trial Summary
This trial is comparing two different combinations of drugs to see which is more effective in treating patients with multiple myeloma.
MonumenTAL-3 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMonumenTAL-3 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MonumenTAL-3 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has worsened after my last treatment, as confirmed by my doctor.I have taken less than 140 mg of steroids like prednisone in the last 2 weeks.I have been treated with pomalidomide before.I am not allergic or intolerant to the ingredients of the study drug.My condition is officially diagnosed as multiple myeloma.I've had treatment for myeloma that included a proteasome inhibitor and lenalidomide.My condition did not improve after treatment with a CD38 antibody.My condition has not improved or has worsened despite treatment.My blood or urine tests show signs of disease.I can take care of myself and am up and about more than half of my waking hours.My multiple myeloma has spread to my brain or spinal cord.I have a specific blood disorder diagnosis.
- Group 1: Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd)
- Group 2: Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP)
- Group 3: Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
At how many different medical facilities can patients participate in this clinical trial?
"The study has 27 sites with active recruitment, these include University Hospitals Cleveland Medical Center, OhioHealth, Baptist Cancer Center and 24 other locations."
What is the estimated capacity of this clinical trial?
"Affirmative, the listing on clinicaltrials.gov reveals that this study is presently recruiting patients. This research project was first advertised on 10/13/2022 and updated most recently on 11/3/2022. 810 individuals are needed for the trial which will take place at 27 locations."
Has Talquetamab been accepted by the FDA?
"Talquetamab's safety is estimated to be a 3. This is based off the fact that it is in Phase 3 trials, meaning that there are efficacy data as well as multiple rounds of supportive safety data."
Are we still recruiting patients for this research project?
"The study, which was posted on October 13th 2020 and last updated on November 3rd 2020, is currently seeking participants."
Share this study with friends
Copy Link
Messenger